The Financial Times leads on AstraZeneca's decision to scrap plans for a new vaccine manufacturing plant in Liverpool, calling it "a blow to the government's growth agenda". The paper says executives have warned that policies pursued by the government will make the UK a less attractive place to invest.

Pharmaceutical company AstraZeneca has cancelled a planned 450 million-pound investment in a vaccine manufacturing plant in northwest England.

AstraZeneca is pulling out of its plans to build a £450mn UK vaccine manufacturing plant after months of wrangling with British officials about state investment for the Merseyside project, in a major blow to Prime Minister Sir Keir Starmer’s government.

AstraZeneca has cancelled plans for a £450m vaccine manufacturing plant in Liverpool, blaming a cut in funding from government.

AstraZeneca’s manufacturing will-they-won’t-they within its home country has swung back firmly toward the ‘they won’t’ camp after the British pharma confirmed that it’s ditching a major venture at | AstraZeneca is pulling the plug on a 450 million pound sterling investment at its vaccine production site in England due in large part to the reduction of a planned financial contribution from the U.

AstraZeneca announced it will not proceed with plans for a 450 million pound vaccine manufacturing plant in Speke, Liverpool. The decision was influenced by discussions with the current government and changes in the financial offer.

AstraZeneca is no longer pursuing plans for a 450 million pound ($558.32 million) vaccine manufacturing plant in Speke, Liverpool, a company spokesperson said on Friday.